ライフサイエンスコーパス: schizoaffective

1 sychosis, clinical or genetic high risk, and schizoaffective.

2 ive predictive value=83%) but much lower for schizoaffective and atypical psychoses.

3 We identified cases of schizophrenia, schizoaffective and bipolar disorder aged >/= 15 years i

4 ount for predisposition to schizophrenia and schizoaffective and bipolar disorder and failure to dete

5 with the highest reported frequencies in the schizoaffective and bipolar groups.

6 e searched using the term: (schizophrenia OR schizoaffective) AND (post-mortem OR postmortem) AND hip

7 is of combined mixed-ancestry schizophrenia, schizoaffective, and bipolar cohorts that resulted in th

8 whether operationally defined schizophrenic, schizoaffective, and manic syndromes share genetic risk

9 the genes contributing to RDC schizophrenic, schizoaffective, and manic syndromes.

10 irings of schizophrenic-manic, schizophrenic-schizoaffective, and schizoaffective-manic syndromes bot

11 bipolar I disorder and 274 schizophrenia or schizoaffective Ashkenazi case-parent trios.

12 ined through sibling pairs with bipolar I or schizoaffective bipolar disorder.

13 nd adequate social/vocational functioning; a schizoaffective diagnosis predicted symptom remission.

14 s not observed, which casts further doubt on schizoaffective diagnosis.

15 ere psychosis not otherwise specified (44%), schizoaffective disorder (36%), and brief psychosis (27%

16 a (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to

17 Cases with diagnoses of schizophrenia or schizoaffective disorder (DSM-IIIR criteria) were consid

18 henotypes for probands with schizophrenia or schizoaffective disorder (extensive neocortical or subco

19 y greater from bipolar disorder (z=-0.77) to schizoaffective disorder (manic z=-1.08; depressed z=-1.

20 (N=293), psychotic bipolar disorder (N=227), schizoaffective disorder (manic, N=110; depressed, N=55)

21 outpatients diagnosed with schizophrenia or schizoaffective disorder (mean [SD] age, 46 [11] years;

22 7); schizophrenia, simple schizophrenia, and schizoaffective disorder (n = 178); and all nonaffective

23 ients diagnosed with schizophrenia (n = 49), schizoaffective disorder (n = 37), or bipolar disorder w

24 isorder (n = 37), schizophrenia (n = 29), or schizoaffective disorder (n = 8).

25 s in their first episode of schizophrenia or schizoaffective disorder (N=118) were assessed at baseli

26 cording to DSM-IV as having schizophrenia or schizoaffective disorder (N=155), bipolar disorder with

27 nth follow-up to patients with schizophrenia/schizoaffective disorder (N=225), bipolar disorder with

28 e offspring of mothers with schizophrenia or schizoaffective disorder (N=26) and matched comparison m

29 ed for nonpsychotic bipolar disorder (N=68), schizoaffective disorder (N=31), or schizophrenia (N=536

30 Adults with schizophrenia or schizoaffective disorder (N=481) were randomly assigned

31 icated patients with schizophrenia (N=61) or schizoaffective disorder (N=6).

32 ection sites, patients with schizophrenia or schizoaffective disorder (N=610), their biological relat

33 [65%]), bipolar disorder (n=115 [22%]), and schizoaffective disorder (n=66 [13%]).

34 morbidity, and diagnosis of schizophrenia or schizoaffective disorder (p<0.01 for all contrasts).

35 r disorder (RR, 0.42; 95% CI, 0.17-0.69) and schizoaffective disorder (RR, 0.44; 95% CI, 0.11-0.79) c

36 orders (107 with schizophrenia (SZ), 87 with schizoaffective disorder (SAD), 132 with psychotic bipol

37 was compared between 14 patients with SCZ or schizoaffective disorder (SCZ/SAD) and 17 controls using

38 a superimposed mood syndrome [SZ+; N = 224], schizoaffective disorder [SAD; N = 129] and bipolar I di

39 s: (1) 170 individuals with schizophrenia or schizoaffective disorder and (2) 84 patients with broad

40 out including 10,925 cases with BPAD, SZ, or schizoaffective disorder and 16,747 controls.

41 Eighteen individuals with schizophrenia or schizoaffective disorder and 19 healthy control particip

42 nsisted of 23 patients with schizophrenia or schizoaffective disorder and 19 non-psychiatric voluntee

43 nts in the first episode of schizophrenia or schizoaffective disorder and 22 healthy comparison subje

44 Twenty-seven patients with schizophrenia or schizoaffective disorder and 23 healthy controls.

45 In 24 patients with schizophrenia or schizoaffective disorder and 25 healthy comparison subje

46 with a DSM-IV diagnosis of schizophrenia or schizoaffective disorder and 26 healthy volunteers parti

47 ata for 3,945 subjects with schizophrenia or schizoaffective disorder and 3,611 screened comparison s

48 tudied 127 outpatients with schizophrenia or schizoaffective disorder and 30 healthy comparison subje

49 relates in 33 patients with schizophrenia or schizoaffective disorder and 31 healthy comparison subje

50 Forty-four patients with schizophrenia or schizoaffective disorder and 34 healthy comparison subje

51 tal cortex from 37 people with schizophrenia/schizoaffective disorder and 37 matched controls.

52 ged and older patients with schizophrenia or schizoaffective disorder and 38 normal comparison subjec

53 essed in 149 consumers with schizophrenia or schizoaffective disorder and 50 healthy control subjects

54 ort of 524 individuals with schizophrenia or schizoaffective disorder and 573 control subjects.

55 ction from 62 subjects with schizophrenia or schizoaffective disorder and 62 matched healthy comparis

56 a subset of 59 people with schizophrenia or schizoaffective disorder and 65 healthy controls, and pr

57 the plasma of 78 patients with schizophrenia/schizoaffective disorder and 73 healthy controls.

58 dication-free patients with schizophrenia or schizoaffective disorder and 74 healthy comparison indiv

59 btained from 96 people with schizophrenia or schizoaffective disorder and 83 healthy controls.

60 , 18-51 years; 59 men) with schizophrenia or schizoaffective disorder and 87 healthy controls (mean [

61 0) sibling pair studies of schizophrenia and schizoaffective disorder and a comparable study of bipol

62 medicated, outpatients with schizophrenia or schizoaffective disorder and a Repeatable Battery for th

63 psychiatric disorders, mainly schizophrenia, schizoaffective disorder and bipolar disorder.

64 individuals diagnosed with schizophrenia or schizoaffective disorder and in 197 healthy comparison s

65 individuals diagnosed with schizophrenia or schizoaffective disorder and in 197 healthy comparison s

66 men comorbid for DSM-III-R schizophrenia or schizoaffective disorder and lifetime alcohol abuse or d

67 ants included 56 women with schizophrenia or schizoaffective disorder and marked symptom severity des

68 ction from 36 subjects with schizophrenia or schizoaffective disorder and matched normal comparison s

69 Twenty-four patients with schizophrenia or schizoaffective disorder and medication-resistant AHs we

70 atients with first-episode schizophrenia and schizoaffective disorder and potential predictors of res

71 who met DSM-IV criteria for schizophrenia or schizoaffective disorder and retrospective and prospecti

72 A boundary between schizoaffective disorder and schizophrenia was not obser

73 h diagnoses of bipolar disorder, depression, schizoaffective disorder and schizophrenia).

74 viduals with DSM-IV-defined schizophrenia or schizoaffective disorder and their mothers underwent a 4

75 Affairs (VA) system who had schizophrenia or schizoaffective disorder and who had been hospitalized w

76 nsider 166 persons who have schizophrenia or schizoaffective disorder and who have had either their g

77 nergic mechanisms to treat schizophrenia and schizoaffective disorder appears indicated.

78 Established nosology identifies schizoaffective disorder as a distinct category with bou

79 assess the rationale for the continuation of schizoaffective disorder as a legitimate diagnostic cate

80 were diagnosed with either schizophrenia or schizoaffective disorder as defined by the DSM-IV.

81 me, however, have questioned the validity of schizoaffective disorder as separate from psychotic mood

82 attempts in patients with schizophrenia and schizoaffective disorder at high risk for suicide.

83 mately 50% of patients with schizophrenia or schizoaffective disorder attempt suicide, and approximat

84 Subtypes of BD including schizoaffective disorder bipolar type (SAB), bipolar I d

85 RNA levels were 13.6% lower in subjects with schizoaffective disorder but did not differ in subjects

86 dysregulation of calreticulin homeostasis in schizoaffective disorder by both genetic and functional

87 SZ: OR = 2.40, p = 1.3 x 10(-4); SZ, BD, and schizoaffective disorder combined: OR = 1.87, p = 8 x 10

88 Twenty-six patients with schizophrenia and schizoaffective disorder completed a task requiring alte

89 The diagnosis of schizoaffective disorder depends on the disease specific

90 hospitalized patients with schizophrenia or schizoaffective disorder during a randomized double-blin

91 The patients with schizophrenia or schizoaffective disorder exhibited less accuracy and spe

92 The schizophrenia or schizoaffective disorder group exhibited decreased power

93 The schizoaffective disorder group was split, with six subje

94 the schizophrenia, simple schizophrenia, and schizoaffective disorder group were inversely related (b

95 The diagnosis of schizoaffective disorder has long maintained an uncertai

96 n this mutation in the calreticulin gene and schizoaffective disorder has remained speculative.

97 ents with clinically stable schizophrenia or schizoaffective disorder have a lower risk of relapse if

98 However, because most prior studies of schizoaffective disorder have only evaluated differences

99 2q11 microdeletions develop schizophrenia or schizoaffective disorder in adolescence and adulthood.

100 iated with the diagnosis of schizophrenia or schizoaffective disorder in the white subset of the stud

101 revious studies, these findings suggest that schizoaffective disorder is associated with lower levels

102 uggest that negative affect in schizophrenia/schizoaffective disorder is associated-directly or indir

103 s of rarity between them and suggesting that schizoaffective disorder is not a separate, 'bona-fide'

104 r, the interrater reliability for diagnosing schizoaffective disorder is very low.

105 Patients diagnosed with schizoaffective disorder likely suffer from a psychotic

106 Contrary to earlier formulations, schizoaffective disorder may be a more severe form of il

107 that hippocampal volume in schizophrenia or schizoaffective disorder may be linked to time of diseas

108 These results suggest that schizoaffective disorder may possess distinct features.

109 Furthermore, patients with a diagnosis of schizoaffective disorder or a history of at least one ma

110 t of other variables, such as a diagnosis of schizoaffective disorder or medication use at the time o

111 re adult men and women with schizophrenia or schizoaffective disorder or non-psychiatric control subj

112 ht outpatients with chronic schizophrenia or schizoaffective disorder over 16 weeks.

113 One hundred patients with schizophrenia or schizoaffective disorder participated in an 8 week, doub

114 tivity (rsfMRI) approach in 84 schizophrenia/schizoaffective disorder patients and 66 healthy compari

115 positive psychotic symptoms in schizophrenia/schizoaffective disorder patients at 24 months suggests

116 ed (125 SZ, 120 bipolar disorder [BD] and 36 schizoaffective disorder patients vs. 467 unaffected adu

117 than the other two groups, and schizophrenia/schizoaffective disorder patients with baseline panic sy

118 Finally, within the schizophrenic/schizoaffective disorder patients, smaller hippocampal v

119 Subjects with schizoaffective disorder performed significantly worse t

120 SZ probands, n = 224; PBD probands, n = 190; schizoaffective disorder probands, n = 142; unaffected r

121 ome among outpatients with schizophrenia and schizoaffective disorder receiving clozapine with a matc

122 ple of 162 outpatients with schizophrenia or schizoaffective disorder recruited from four sites.

123 generally better preserved in patients with schizoaffective disorder relative to patients with schiz

124 relatives, n = 195; PBD relatives, n = 175; schizoaffective disorder relatives, n = 113]; control su

125 present or present to a lesser degree in the schizoaffective disorder subjects (diagnosis of schizoaf

126 iously reported linkage of schizophrenia and schizoaffective disorder to 13q32-34 in the European des

127 cal and biological features of patients with schizoaffective disorder to patients with related disord

128 able condition with chronic schizophrenia or schizoaffective disorder to receive treatment with flexi

129 we have also found linkage of schizophrenia/schizoaffective disorder to this same chromosomal region

130 patients with early-onset schizophrenia and schizoaffective disorder to treatment with either olanza

131 Schizoaffective disorder unifies schizophrenia and bipol

132 Schizoaffective disorder was associated with low emotion

133 for the phenotype of DSM-IV schizophrenia or schizoaffective disorder was found in a region on chromo

134 Schizoaffective disorder was named as a compromise diagn

135 izoaffective disorder subjects (diagnosis of schizoaffective disorder was the most significant covari

136 rty-three outpatients with schizophrenia and schizoaffective disorder were categorized into deficit a

137 schizophrenia, schizophreniform disorder, or schizoaffective disorder were evaluated during their fir

138 Thirty patients with schizophrenia or schizoaffective disorder were investigated.

139 The characteristics of schizoaffective disorder were more often similar to schi

140 mRNA and protein levels within subjects with schizoaffective disorder were not attributable to factor

141 y-five patients with DSM-IV schizophrenia or schizoaffective disorder were randomly assigned for 9 mo

142 Sixty-nine people with schizophrenia or schizoaffective disorder were randomly assigned to 36 se

143 Sixty-five patients with schizophrenia or schizoaffective disorder were randomly assigned to NET p

144 7) outpatients with chronic schizophrenia or schizoaffective disorder were randomly assigned to recei

145 who met DSM-IV criteria for schizophrenia or schizoaffective disorder were randomly assigned to recei

146 outpatients with DSM-III-R schizophrenia or schizoaffective disorder were randomly assigned to recei

147 lly stable outpatients with schizophrenia or schizoaffective disorder were randomly assigned to train

148 total of 181 patients with schizophrenia or schizoaffective disorder were recruited from three clini

149 SFs of the individuals with schizophrenia or schizoaffective disorder were related to those of the hu

150 ia for treatment-refractory schizophrenia or schizoaffective disorder were studied.

151 cing their first episode of schizophrenia or schizoaffective disorder were treated first with clozapi

152 tients meeting criteria for schizophrenia or schizoaffective disorder who had residual symptoms despi

153 cessation in patients with schizophrenia or schizoaffective disorder who were also treated with the

154 were adults diagnosed with schizophrenia or schizoaffective disorder who were clinically assessed to

155 lve patients with DSM-IV bipolar disorder or schizoaffective disorder who were clinically stable whil

156 cing their first episode of schizophrenia or schizoaffective disorder who were given fluphenazine as

157 treatment in patients with schizophrenia and schizoaffective disorder who were hospitalized or at hig

158 d fifty-seven patients with schizophrenia or schizoaffective disorder who were inpatients at four hos

159 ly assaultive subjects with schizophrenia or schizoaffective disorder who were inpatients in state ps

160 Thirty patients with schizophrenia or schizoaffective disorder who were receiving clozapine mo

161 Patients with schizophrenia or schizoaffective disorder with a body mass index >/= 27 a

162 ded schizophrenia, simple schizophrenia, and schizoaffective disorder with poor outcome.

163 severity continuum (schizophrenia worse than schizoaffective disorder worse than bipolar psychosis);

164 mple included 1,870 cases (schizophrenia and schizoaffective disorder) and 2,002 screened comparison

165 SZ (including a subgroup diagnosed as having schizoaffective disorder) and 26 age-matched and sex-mat

166 patients with diagnoses of schizophrenia or schizoaffective disorder) completed the Sternberg Item-R

167 in a live cohort of psychosis (schizophrenia/schizoaffective disorder) subjects.

168 sensus diagnosis of schizophrenia (including schizoaffective disorder) using DSM-III or DSM-IV criter

169 e (as a part of major depressive disorder or schizoaffective disorder) were at a greater risk for sui

170 spectrum disorders (mostly schizophrenia and schizoaffective disorder) who had available second-trime

171 re mental illness (46% with schizophrenia or schizoaffective disorder) who had not obtained or kept c

172 disorder with psychosis and schizophrenia or schizoaffective disorder), 192 presenting with a primary

173 arrow phenotype psychosis (schizophrenia and schizoaffective disorder), broad psychosis, and control

174 esponse were diagnosis (schizophrenia versus schizoaffective disorder), premorbid functioning, durati

175 spectrum disorders (mostly schizophrenia and schizoaffective disorder).

176 spectrum disorders (mostly schizophrenia and schizoaffective disorder).

177 d group of 21 subjects with schizophrenia or schizoaffective disorder, 11 subjects with schizotypal p

178 randomization, 58.1% had schizophrenia or a schizoaffective disorder, 22.0% had bipolar disorder, an

179 ducted in 980 patients with schizophrenia or schizoaffective disorder, 26.8% of whom were refractory

180 reviously reported): 19 patients with SCZ or schizoaffective disorder, 30 unaffected first-degree rel

181 g pairs with a diagnosis of schizophrenia or schizoaffective disorder, 396 highly polymorphic markers

182 comprising 42 patients with schizophrenia or schizoaffective disorder, 57 of their unaffected first-d

183 bipolar disorder with psychotic features, or schizoaffective disorder, and 10,195 population control

184 h psychosis (146 with schizophrenia, 90 with schizoaffective disorder, and 115 with psychotic bipolar

185 with schizophrenia, 106 of individuals with schizoaffective disorder, and 129 of individuals with ps

186 tients with schizophrenia, 103 patients with schizoaffective disorder, and 129 patients with psychoti

187 nts met DSM-IV criteria for schizophrenia or schizoaffective disorder, and 21 nonpsychiatric voluntee

188 atients with schizophrenia, 32 patients with schizoaffective disorder, and 40 patients with bipolar d

189 ely 65% of participants had schizophrenia or schizoaffective disorder, and 85.5% were receiving conco

190 Schizophrenia, schizoaffective disorder, and bipolar disorder are commo

191 collected on individuals with schizophrenia, schizoaffective disorder, and bipolar disorder with psyc

192 nd exon 9 are associated with schizophrenia, schizoaffective disorder, and bipolar disorder.

193 nical phenotype of psychosis (schizophrenia, schizoaffective disorder, and bipolar I disorder with ps

194 People with schizophrenia, schizoaffective disorder, and bipolar illness share clin

195 sychotic disorders (including schizophrenia, schizoaffective disorder, and psychotic bipolar disorder

196 bipolar I, bipolar II with major depression, schizoaffective disorder, and recurrent unipolar disorde

197 bipolar disorder, major depressive disorder, schizoaffective disorder, and schizophrenia) in male par

198 probands (60 with schizophrenia and 12 with schizoaffective disorder, ascertained so as to be repres

199 meeting DSM-IV criteria for schizophrenia or schizoaffective disorder, assessed during acute admissio

200 and three psychotic disorders--schizophrenia/schizoaffective disorder, bipolar disorder with psychosi

201 ss as a clinical diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, or other psy

202 9), bipolar disorder (DSM-IV-TR) (N=40), and schizoaffective disorder, bipolar type (N=18).

203 probands with bipolar I disorder (N=192) and schizoaffective disorder, bipolar type, (N=11) were incl

204 bipolar I disorder; bipolar II disorder; or schizoaffective disorder, bipolar type, according to DSM

205 ion to antipsychotic action in patients with schizoaffective disorder, bipolar type, and bipolar I di

206 nd bipolar disorder and parses patients with schizoaffective disorder, bipolar type, into two subgrou

207 d aim was to determine whether subjects with schizoaffective disorder, bipolar type, were neurophysio

208 ive disorder and a sibling with bipolar I or schizoaffective disorder, bipolar type.

209 is of a major affective disorder (BP type I; schizoaffective disorder, bipolar type; BP type II; or m

210 models (ASMs) were considered: ASM1 (BPI and schizoaffective disorder, BP cases (SABP) only), ASM2 (A

211 and in patients with schizophrenia (N=12) or schizoaffective disorder, depressed type (N=4), during a

212 nostic Criteria major depressive disorder or schizoaffective disorder, depressed type, entered a long

213 atients with a diagnosis of schizophrenia or schizoaffective disorder, depressed type.

214 -six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and

215 In the subjects with schizoaffective disorder, mean GAD65 protein levels were

216 psychotic disorders (schizophrenia, n = 219; schizoaffective disorder, n = 142; and psychotic bipolar

217 phrenia spectrum disorder (schizophrenia and schizoaffective disorder, n = 23) and healthy controls (

218 7 schizophrenia cases (schizophrenia, N=630; schizoaffective disorder, N=147) with maternal sera avai

219 trial included patients with schizophrenia, schizoaffective disorder, or a mood disorder who had mod

220 o had received a diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder.

221 d first-degree relatives with schizophrenia, schizoaffective disorder, or bipolar disorder.

222 nths; a clinical diagnosis of schizophrenia, schizoaffective disorder, or delusional disorder; and a

223 participants with underlying schizophrenia, schizoaffective disorder, or mood disorder.

224 of patients hospitalized for schizophrenia, schizoaffective disorder, or nonpsychotic bipolar disord

225 1239 cases with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder;

226 ited 933 stable probands with schizophrenia, schizoaffective disorder, or psychotic bipolar I disorde

227 ients with a first episode of schizophrenia, schizoaffective disorder, or schizophreniform disorder (

228 had a DSM-III-R diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder a

229 who were later diagnosed with schizophrenia, schizoaffective disorder, or schizophreniform disorder,

230 riptome signatures are not characteristic of schizoaffective disorder, providing a potential molecula

231 netic, reveals multiple similarities between schizoaffective disorder, schizophrenia and psychotic bi

232 Inpatient diagnoses of bipolar disorder, schizoaffective disorder, schizophrenia, and other nonaf

233 In adults with schizophrenia or schizoaffective disorder, use of paliperidone palmitate

234 ved a research diagnosis of schizophrenia or schizoaffective disorder, whereas 44% of patients with n

235 The diagnosis of schizoaffective disorder, which can result in substandar

236 ht outpatients with chronic schizophrenia or schizoaffective disorder.

237 h analysis of 4084 samples with BPAD, SZ, or schizoaffective disorder.

238 and cognitive functions in schizophrenia and schizoaffective disorder.

239 asive nicotinic effects in schizophrenia and schizoaffective disorder.

240 ican American probands with schizophrenia or schizoaffective disorder.

241 r predisposition genes for schizophrenia and schizoaffective disorder.

242 e treatment of early-onset schizophrenia and schizoaffective disorder.

243 e for treating early-onset schizophrenia and schizoaffective disorder.

244 olescents with early-onset schizophrenia and schizoaffective disorder.

245 otics to treat early-onset schizophrenia and schizoaffective disorder.

246 tpatients with diagnoses of schizophrenia or schizoaffective disorder.

247 age and older patients with schizophrenia or schizoaffective disorder.

248 ficacy in the treatment of schizophrenia and schizoaffective disorder.

249 cs of ASP4345 in patients with schizophrenia/schizoaffective disorder.

250 e intron 1/exon 2 region in individuals with schizoaffective disorder.

251 acutely ill inpatients with schizophrenia or schizoaffective disorder.

252 tion of the exon 9 missense allele Phe607 in schizoaffective disorder.

253 patients with diagnoses of schizophrenia or schizoaffective disorder.

254 ent of the first episode of schizophrenia or schizoaffective disorder.

255 with acute exacerbation of schizophrenia or schizoaffective disorder.

256 e and negative symptoms in schizophrenia and schizoaffective disorder.

257 ressive disorder (MDD), bipolar disorder, or schizoaffective disorder.

258 nt of patients with chronic schizophrenia or schizoaffective disorder.

259 f relapse in patients with schizophrenia and schizoaffective disorder.

260 dividuals with recent-onset schizophrenia or schizoaffective disorder.

261 cognition in patients with schizophrenia or schizoaffective disorder.

262 ords of 82 outpatients with schizophrenia or schizoaffective disorder.

263 ponse to a first episode of schizophrenia or schizoaffective disorder.

264 up (68% of survivors); 175 had schizophrenia/schizoaffective disorder.

265 ume was found in patients with schizophrenia/schizoaffective disorder.

266 sfunction in patients with schizophrenia and schizoaffective disorder.

267 years of age or older with schizophrenia or schizoaffective disorder.

268 cluded 287 individuals with schizophrenia or schizoaffective disorder.

269 he abnormalities were similar between SZ and schizoaffective disorder.

270 ohort, 4310 developed bipolar disorder; 784, schizoaffective disorder; 4823, schizophrenia; and 5013,

271 .5% met DSM-IV criteria for schizophrenia or schizoaffective disorder; 55.8%, for major affective dis

272 ence; 64 men with DSM-III-R schizophrenia or schizoaffective disorder; 62 men with Research Diagnosti

273 samples (528 UK patients with schizophrenia/schizoaffective disorder; 921 German participants includ

274 ID1) met this criterion for schizophrenia or schizoaffective disorder; five replicate previous associ

275 (SZ), psychotic bipolar disorder (PBD), and schizoaffective disorder; their first-degree relatives;

276 al regions were limited to schizophrenia and schizoaffective disorders (P < .001).

277 Bipolar, schizophrenia, and schizoaffective disorders are common, highly heritable p

278 Individuals with schizophrenia or schizoaffective disorders were included as cases.

279 ntal illness (defined here as schizophrenia, schizoaffective disorders, and bipolar affective disorde

280 hotic disorders, including schizophrenia and schizoaffective disorders.

281 s significantly higher for the patients with schizoaffective illness than for those with bipolar diso

282 ated probands with bipolar I, bipolar II, or schizoaffective-manic disorder and 63 comparison subject

283 ic-manic, schizophrenic-schizoaffective, and schizoaffective-manic syndromes both within probands and

284 ght patients meeting the DSM-IV criteria for schizoaffective or bipolar disorder that was deemed trea

285 teria (RDC) for lifetime-ever schizophrenic, schizoaffective, or manic syndrome were ascertained from

286 brain were obtained for 64 schizophrenic or schizoaffective patients (representative of all such pro

287 Fourteen stable, medicated schizophrenia/schizoaffective patients and 13 healthy comparison subje

288 was assessed in a cohort of 40 schizophrenia/schizoaffective patients relative to 42 healthy control

289 Schizophrenia/schizoaffective patients show highly significant deficit

290 s were NCT01474395/NCT02156908 Schizophrenia/schizoaffective patients showed significantly reduced au

291 In a second cohort (n = 21 schizophrenia/schizoaffective patients, n = 13 healthy controls), even

292 Across DSM-IV diagnoses, schizophrenia and schizoaffective probands showed overlapping gray matter

293 Schizophrenia and schizoaffective probands versus healthy controls showed

294 risk for recurrent unipolar (RUP), BIP, and schizoaffective (SA) disorders, while relatives of schiz

295 .4 for rs722642 at 78 cM) using only BPI and schizoaffective (SA), BP cases.

296 pectrum of mood disorders (that is, bipolar, schizoaffective (SAF), major depression) based on contem

297 syndromes, but the genetic liability to the schizoaffective syndrome was entirely shared in common w

298 In contrast, environmental liability to the schizoaffective syndrome was not shared with the other s

299 nia, and are scant for psychotic bipolar and schizoaffective (SZA) disorders and for relatives of the

300 Schizophrenia (SZ), schizoaffective (SZA), and bipolar (BP) disorder are neu